CRISPR Therapeutics AG — Director's Dealing 2025

Jun 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2025-06-05

Reporting Person: Rommel Christian (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-05	Stock Option (Right to Buy)	$38.57	A	13000	Acquired	2035-06-05	Common Shares (13000)	Direct

Footnotes

F1: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders.